- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02469532
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or atherectomy-based revascularization procedures.
- To observe the femoropopliteal revascularization outcomes post-angioplasty and/or atherectomy and to observe potential correlation between patency outcomes and the levels of MCP-1, C-reactive protein and MMP-9 from baseline to 24 hours and 30 days post-procedure.
- To provide a comparator dataset to the investigational DANCE trial, which has the same enrollment criteria as this observational trial but includes the investigational use of a local drug therapy to limit inflammation caused by mechanical revascularization.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Arkansas Heart Hospital
-
-
Louisiana
-
Bossier City, Louisiana, Forenede Stater, 7111
- Endovascular Technologies (Willis Knighton Medical Center)
-
-
Mississippi
-
Hattiesburg, Mississippi, Forenede Stater, 39401
- Hattiesburg Clinic
-
-
North Carolina
-
Raleigh, North Carolina, Forenede Stater
- Rex Hospital
-
-
Texas
-
New Braunfels, Texas, Forenede Stater, 78130
- Mission Research Institute
-
Palestine, Texas, Forenede Stater, 75801
- Palestine Regional Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
Screening Criteria
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb.
- Patient is willing to provide informed consent and comply with the required follow up visits Procedural Criteria
- De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
- >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3mm and ≤ 8mm
- Successful wire crossing of lesion
- A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)
Exclusion Criteria:
Screening Criteria
- Pregnant, nursing or planning on becoming pregnant in < 2years
- Life expectancy of <2 years
- Known active malignancy
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR <29
- Prior bypass surgery, drug-coated balloon or stenting of the target lesion
- Contra-indication or known hypersensitivity to contrast media or physician prescribed antiplatelet regimen as applicable
- Systemic fungal infection
- Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
- Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
- Acute limb ischemia
- Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
- Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial Procedural Criteria
- Lesions extending into the trifurcation or above the profunda
- Heavy eccentric or moderate circumferential calcification at index lesion
- Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
- Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
- Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Atherectomy
Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures. |
Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
|
|
Angioplasty
Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures. |
Device: Balloon Angioplasty Selection is driven by preference of the operator
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in inflammatory biomarkers
Tidsramme: Baseline to 24-hours post-procedure and 30-days post-procedure
|
Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
|
Baseline to 24-hours post-procedure and 30-days post-procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Target Lesion Revascularization
Tidsramme: 6 and 12 months post-procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the restenosis rates in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
|
6 and 12 months post-procedure
|
|
Comparing biomarker (hs-CRP, MCP-1 and MMP-9) results
Tidsramme: Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the correlation between the levels of MCP-1, C-reactive protein and MMP-9 after angioplasty or atherectomy procedures in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
Objective measurement of biomarkers will be performed by a contract laboratory to avoid bias.
|
Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jason A Yoho, MD, Mission Research, New Braunfels, TX
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CIP0181
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Perifer arteriel sygdom
-
Mayo ClinicTilmelding efter invitationAnatomi af GSV for Rescue Peripheral IV AccessForenede Stater
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada og andre samarbejdspartnereRekrutteringTwin Reversal Arterial Perfusion SyndromeSpanien, Tyskland, Israel, Belgien, Holland, Canada, Forenede Stater, Østrig, Frankrig, Italien, Det Forenede Kongerige
-
Nanfang Hospital, Southern Medical UniversityRekrutteringBevacizumab | Hepatecellular carcinoma | QL1706 | RALOX-HAIC (Hepatic Arterial Infusion Chemoterapi med Raltitrexed og Oxaliplatin) | Type VP3/4 Portalvene Tumor Trombose | Iparomlimab og Tuvonralimab-injektionKina
-
University of MiamiAktiv, ikke rekrutterendeTvilling til tvilling transfusionssyndrom | Tvilling; Komplicerer graviditet | Twin Reversal Arterial Perfusion Syndrome | Monokorionisk diamniotisk placenta | Monokorial monoamniotisk placentaForenede Stater
-
Boston Children's HospitalRekrutteringGraviditetsrelateret | Moderlige; Procedure | Fostertilstande | Twin Monochorionic Monoamniotic Placenta | Tvilling til tvilling transfusionssyndrom | Twin Reversal Arterial Perfusion Syndrome | Vasa Previa | In utero-procedure, der påvirker foster eller nyfødte | Chorion; Abnorm | ChorioangiomForenede Stater
Kliniske forsøg med Atherectomy System
-
Columbia UniversityAfsluttetKoronararteriesygdom (CAD)Forenede Stater
-
Abbott Medical DevicesAfsluttetPerifer arteriesygdomForenede Stater
-
Avinger, Inc.Trukket tilbagePerifer arteriel sygdomNew Zealand
-
Boston Scientific CorporationAfsluttetPerifer arteriel sygdomJapan
-
Boston Scientific CorporationAfsluttet
-
Boston Scientific CorporationAfsluttet
-
Medtronic EndovascularAfsluttetPerifer arteriel sygdom | Claudication | Kritisk lemmeriskæmi
-
Rex MedicalSyntactxAfsluttetPerifer arteriesygdomForenede Stater
-
Eximo Medical Ltd.AfsluttetPADForenede Stater, Østrig, Italien